Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
GTBP Stock Summary
Top 10 Correlated ETFs
GTBP
In the News
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy
GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Dr. Jeffrey Miller, MD, GT Bipharma's Consulting Chief Medical Officer and Chief Scientific Officer, will present a corporate overview at H.C. Wainwright's Cell Therapy Virtual Conference taking place on February 28, 2023. Company management will also be participating in 1x1 meetings during the event.
GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September
BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that management will present in-person at H.C. Wainwright's 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace. Company management will also be participating in 1x1 meetings during the event.
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference
BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced that management will present at H.C. Wainwright's Hybrid Global Investment Conference. The conference will take place May 23-26, 2022 at the Fontainebleau, Miami Beach Hotel, Miami Beach, Florida.
GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences
BRISBANE, Calif., Feb. 24, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that GT Biopharma will be participating in the following upcoming medical conferences: Abstract and poster presentation details are as follows: ESMO Targeted Anticancer Therapies Congress (TAT) (March 7-8, 2022) Title: Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE) Abstract Number: 250 Session: Immunotherapy Presentation Type: Poster Session Date and Time: March 7, 9:20AM (CET) (On-demand e-poster display) Location: Virtual Poster Board Number: 17P 48th Annual European Society for Blood and Marrow Transplantation (EBMT) (March 19-23, 2022) Title: A Tri-specific Killer Engager (TriKE) against B7-H3 enhances NK cell mediated killing of multiple myeloma Abstract Number: AS-EBMT-2022-00508 Session: New Drugs- and Cell-Based Immune Therapies Presentation Type: Poster Session Date and Time: March 19, 2022, 9:50 AM (CET) Location: Prague Congress Center, Czech Republic Poster Board Number: P153 American Association for Cancer Research (AACR) Annual Meeting (April 8-13, 2022) Title: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas Abstract Number: Abstract control number 3334, permanent abstract number 3435 Session: Clinical Research Excluding Trials, Combination Immunotherapies / Therapeutic Antibodies Presentation Type: Poster Session Date and Time: April 12, 2022 1:30 PM – 5:00 PM Location: Ernest N.
GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference
BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® protein biologic technology platform, announced today that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B.
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness
GT BioPharma's Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021
BEVERLY HILLS, Calif., Sept. 20, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced Dr. Jeffrey Miller's mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021.
OXIS International Inc. (GTBP) Moves to Buy: Rationale Behind the Upgrade
OXIS International Inc. (GTBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GTBP Financial details
GTBP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -87.7 | -12.04 | -7.21 | -2.08 | -0.64 | |
Operating cash flow per share | -3.61 | -1.08 | -1.66 | -0.55 | -0.48 | |
Free cash flow per share | -3.62 | -1.08 | -1.66 | -0.55 | -0.48 | |
Cash per share | 0.02 | 0.01 | 1.21 | 1.14 | 0.52 | |
Book value per share | 3.9 | -5.65 | -6.67 | 0.78 | 0.37 | |
Tangible book value per share | -4.7 | -5.7 | -6.71 | 0.78 | 0.37 | |
Share holders equity per share | 3.9 | -5.65 | -6.67 | 0.78 | 0.37 | |
Interest debt per share | 6.74 | 4.57 | 6.76 | 0.03 | 0.01 | |
Market cap | 979.69M | 139.85M | 948.26M | 2.58B | 846.73M | |
Enterprise value | 990.43M | 153.18M | 969.3M | 2.57B | 841.24M | |
P/E ratio | -3.78 | -3.43 | -29.99 | -43.89 | -41.3 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -91.76 | -38.22 | -130.58 | -165.08 | -55.64 | |
PFCF ratio | -91.45 | -38.22 | -130.58 | -165.08 | -55.64 | |
P/B Ratio | 84.9 | -7.31 | -32.4 | 117.58 | 72.16 | |
PTB ratio | 84.9 | -7.31 | -32.4 | 117.58 | 72.16 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -45.97 | -13.37 | -50.06 | -44.67 | -40.13 | |
EV to operating cash flow | -92.76 | -41.86 | -133.48 | -164.51 | -55.28 | |
EV to free cash flow | -92.45 | -41.86 | -133.48 | -164.51 | -55.28 | |
Earnings yield | -0.26 | -0.29 | -0.03 | -0.02 | -0.02 | |
Free cash flow yield | -0.01 | -0.03 | -0.01 | -0.01 | -0.02 | |
Debt to equity | 0.94 | -0.7 | -0.9 | 0 | 0.01 | |
Debt to assets | 0.43 | 33.73 | 4.65 | 0 | 0.01 | |
Net debt to EBITDA | -0.5 | -1.16 | -1.09 | 0.16 | 0.26 | |
Current ratio | 0.01 | 0.01 | 0.16 | 3.14 | 3.35 | |
Interest coverage | -27.43 | -7.55 | -2.04 | -80.1 | -2.66K | |
Income quality | 0.04 | 0.09 | 0.26 | 0.27 | 0.73 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.99 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -5.14 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 87.78 | 39.14 | 32.9 | 6.04 | 2.31 | |
ROIC | -1.32 | 2.99 | 2.58 | -2.65 | -1.73 | |
Return on tangible assets | -1.89K | -102.97 | -5.58 | -1.82 | -1.23 | |
Graham Net | -4.73 | -5.81 | -6.79 | 0.77 | 0.36 | |
Working capital | -13.94M | -19.43M | -29.43M | 21.91M | 11.62M | |
Tangible asset value | -13.89M | -19.31M | -29.43M | 21.91M | 11.73M | |
Net current asset value | -13.94M | -19.43M | -29.43M | 21.91M | 11.56M | |
Invested capital | 0.94 | -0.7 | -0.9 | 0 | 0.01 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 2.15M | 1.85M | 2.09M | 5.22M | 5.66M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 177.03K | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -22.46 | 2.13 | 1.08 | -2.68 | -1.75 | |
Capex per share | -0.01 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.21 | -0.17 | -0.1 | -0.05 | -0.06 | |
Operating cash flow per share | -0.09 | -0.13 | -0.07 | -0.05 | -0.05 | |
Free cash flow per share | -0.09 | -0.13 | -0.07 | -0.05 | -0.05 | |
Cash per share | 0.66 | 0.52 | 0.51 | 0.45 | 0.39 | |
Book value per share | 0.51 | 0.37 | 0.33 | 0.29 | 0.24 | |
Tangible book value per share | 0.51 | 0.37 | 0.33 | 0.29 | 0.24 | |
Share holders equity per share | 0.51 | 0.37 | 0.33 | 0.29 | 0.24 | |
Interest debt per share | 0.01 | 0.01 | 0.01 | 0 | 0 | |
Market cap | 1.66B | 846.73M | 644.91M | 376.02M | 296.55M | |
Enterprise value | 1.65B | 841.24M | 643.01M | 373.37M | 293.99M | |
P/E ratio | -62.46 | -38.83 | -41.27 | -47.19 | -30.69 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -567.82 | -197.01 | -221.92 | -194.32 | -150.99 | |
PFCF ratio | -567.82 | -197.01 | -221.92 | -194.32 | -150.99 | |
P/B Ratio | 103.85 | 72.16 | 49.41 | 31.97 | 29.64 | |
PTB ratio | 103.85 | 72.16 | 49.41 | 31.97 | 29.64 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -239.25 | -149.23 | -183.67 | -109.78 | -94.17 | |
EV to operating cash flow | -567.04 | -195.73 | -221.27 | -192.96 | -149.69 | |
EV to free cash flow | -567.04 | -195.73 | -221.27 | -192.96 | -149.69 | |
Earnings yield | 0 | -0.01 | -0.01 | -0.01 | -0.01 | |
Free cash flow yield | 0 | -0.01 | 0 | -0.01 | -0.01 | |
Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 0.33 | 0.98 | 0.54 | 0.78 | 0.82 | |
Current ratio | 4.15 | 3.35 | 4.89 | 3.72 | 3.15 | |
Interest coverage | -65.64 | -722.25 | -17.29 | -3.62K | 0 | |
Income quality | 0.42 | 0.77 | 12.8 | 0.97 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.55 | 1.19 | 0.87 | 0.57 | 0.57 | |
ROIC | -0.41 | -0.47 | -4.73 | -0.27 | -0.31 | |
Return on tangible assets | -0.31 | -0.33 | -0.19 | -0.11 | -0.15 | |
Graham Net | 0.5 | 0.36 | 0.33 | 0.29 | 0.24 | |
Working capital | 15.85M | 11.62M | 15.86M | 13.18M | 10.96M | |
Tangible asset value | 15.95M | 11.73M | 13.05M | 11.76M | 10.01M | |
Net current asset value | 15.76M | 11.56M | 12.9M | 11.64M | 9.91M | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 5.29M | 3.23M | 3.14M | 3.32M | 3.74M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.42 | -0.46 | -0.3 | -0.17 | -0.24 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
GTBP Frequently Asked Questions
What is GT Biopharma, Inc. stock symbol ?
GT Biopharma, Inc. is a US stock , located in Brisbane of Ca and trading under the symbol GTBP
What is GT Biopharma, Inc. stock quote today ?
GT Biopharma, Inc. stock price is $4.43 today.
Is GT Biopharma, Inc. stock public?
Yes, GT Biopharma, Inc. is a publicly traded company.